---
title: Bioanalysis & Biomarker Services for Biologics | CBS
description: PK, immunogenicity (ADA/NAb) and biomarker assay development and validation for mAbs, ADCs, oligonucleotides and CGT, with LBA, LC-MS and flow cytometry.
image: https://www.crystalbiosolutions.com/hubfs/bioanalytical-and-biomarker.webp
---

![Crystal Bio Solutions logo](https://www.crystalbiosolutions.com/hs-fs/hubfs/Crystal%20Bio%20Solutions%20logo.webp?width=330&height=150&name=Crystal%20Bio%20Solutions%20logo.webp)

- Bioanalysis & Biomarkers 
    - [All Bioanalysis & Biomarker Services](https://www.crystalbiosolutions.com/services/bioanalysis-and-biomarkers)
    - [PK Assays for Biologics & ADCs](https://www.crystalbiosolutions.com/services/pk-bioanalysis)
    - [NAb & ADA Immunogenicity Assays](https://www.crystalbiosolutions.com/ada-and-nab-testing-in-biologics-pk-efficacy-and-regulatory-risk)
    - [Receptor Occupancy Assays](https://www.crystalbiosolutions.com/services/receptor-occupancy-assays)
- Biologics CMC Analytical 
    - [All Biologics CMC Analytical Services](https://www.crystalbiosolutions.com/characterization-cmc-analytical)
    - [Developability Assessment](https://www.crystalbiosolutions.com/services/biologics-developability-assessment)
    - [Extended Characterization by HRMS](https://www.crystalbiosolutions.com/services/biologics-extended-characterization-hrms)
    - [Biotransformation & In Vivo CQA](https://www.crystalbiosolutions.com/services/biotransformation-in-vivo-cqa)
- [Clinical Pharmacology](https://www.crystalbiosolutions.com/services/clinical-pharmacology)
- Solutions 
    - [ADC Programs](https://www.crystalbiosolutions.com/antibody-drug-conjugates-adc)
    - [Regulatory Affairs Support](https://www.crystalbiosolutions.com/services/regulatory-affairs-biologics-adc-cgt)
    - [Clinical Support](https://www.crystalbiosolutions.com/clinical-research-services)

- [Resources](https://www.crystalbiosolutions.com/news-and-events)
- [Case Studies](https://www.crystalbiosolutions.com/news-and-events/tag/case-study)
- [About Us](https://www.crystalbiosolutions.com/about-us)
- [Locations](https://www.crystalbiosolutions.com/locations)
- [Careers](https://www.crystalbiosolutions.com/careers-at-crystal-bio-solutions)
- [Request a Proposal](https://www.crystalbiosolutions.com/contact-us)

![Scientist loading a 96-well plate with a multichannel pipette during bioanalysis sample preparation.](https://www.crystalbiosolutions.com/hs-fs/hubfs/bioanalytical-and-biomarker.webp?width=960&height=640&name=bioanalytical-and-biomarker.webp)

# Bioanalysis and Biomarker Services for Every Drug Development Phase

Crystal Bio Solutions, part of Crystal Group, provides phase-appropriate bioanalytical and biomarker support for complex biologics, ADCs and other modalities. Our laboratory in Pleasanton, California, operates under GLP and GCLP quality frameworks for applicable regulated studies. We develop, qualify, validate and apply PK, immunogenicity, receptor occupancy and biomarker assays, with documentation tailored to the program stage and intended regulatory use. Central lab kit design, cold-chain logistics and chain-of-custody tracking are also available.

[![Let's talk](https://hubspot-no-cache-eu1-prod.s3.amazonaws.com/cta/default/146565877/interactive-264126601418.png)](https://www.crystalbiosolutions.com/hs/cta/wi/redirect?encryptedPayload=AVxigLJhexmpwV7XK4huWoPrLUFdmhffs7P8q%2Bl8WxMihxIQO4gUaxU5SjKFX%2FgJ24qPGAkLBmX6d5a1dhqjDwoU5fi8%2B%2FV2%2BK90oePEfxLHkOx0AJzsqx2m7Gx5%2FryHcyiZHsOBEATLK5sUDKsK%2FjNB5f%2F8a5to5ibkuLog74OKHO7n1VRKIHdPKhZszjmskf1c8QLPWkiM7bVs7cScRLnPsYOzYbaf&webInteractiveContentId=264126601418&portalId=146565877&hsLang=en)

![CBS orange-blue banner-1](https://www.crystalbiosolutions.com/hs-fs/hubfs/CBS%20orange-blue%20banner-1.png?width=2000&height=21&name=CBS%20orange-blue%20banner-1.png "CBS orange-blue banner-1")

Immunoassays Tiered immunoassays in a range of biological matrices using ELISA, MSD, Gyrolab, Luminex and SP-X, including multiplex and high-sensitivity formats. Services cover ADA and NAb assay development, validation and sample analysis, with isotyping, anti-PEG and other characterization assays as needed. LC-MS Triple quadrupole LC-MS/MS (SCIEX 7500) supports sensitive quantitative analysis of peptides, small molecules, biomarkers, oligonucleotides and selected biologic and ADC analytes. High-resolution MS at our Natick, Massachusetts laboratory supports structural characterization and complex analytical investigations. Assay strategy is selected according to analyte, matrix, sensitivity, selectivity and intended use. Cell-based Assays Mechanism-aligned potency and activity readouts that include neutralizing antibody assays, reporter gene systems, and functional pharmacology endpoints. Assays are qualified or validated for phase-appropriate use. Flow Cytometry Multiparameter immunophenotyping and receptor occupancy to support cell therapy and biomarker strategies. Services include panel design, controls and compensation, viability gating, rare-event analysis, and validated analysis templates. ELISpot Assays Quantification of cell-mediated immune responses for vaccines and CGT. Common analytes include IFN-gamma, IL-2, and granzyme B with qualified methods, clear acceptance criteria, and standardized data packages. Molecular Biology qPCR and ddPCR for copy number and biodistribution, RNA-Seq and NanoString for expression profiling, and NGS workflows to support cell and gene therapy programs. Phase-appropriate validation and clear bioinformatics reporting are included.

![CBS orange banner-1](https://www.crystalbiosolutions.com/hs-fs/hubfs/website-assets/CBS%20orange%20banner-1.png?width=2000&height=24&name=CBS%20orange%20banner-1.png "CBS orange banner-1")

![Scientist working in a bioanalysis laboratory (illustrative image)](https://www.crystalbiosolutions.com/hs-fs/hubfs/pexels-pavel-danilyuk-8442153.jpg?width=640&height=480&name=pexels-pavel-danilyuk-8442153.jpg) Immunogenicity Assessment to Support Regulatory Submissions Crystal Bio Solutions supports immunogenicity programs from strategy through reporting.

**What we deliver:**

- Immunogenicity risk assessment and assay strategy aligned to mechanism, patient population and development stage
- Assay development, qualification and validation, including cut-points, sensitivity, drug tolerance and target interference assessments
- Sample analysis: ADA screening, confirmation and titer, NAb analysis, and isotyping or domain specificity when the risk profile calls for it
- Analysis of associations between ADA and PK, PD, efficacy and safety data
- Documentation for submissions, including validation reports, sample analysis plans, data packages, integrated immunogenicity summaries and support for responses to agency questions

## Drug Modalities We Support

Monoclonal Antibodies PK, ADA/NAb and biomarker assays using ligand-binding and LC-MS platforms. ADC Total antibody, conjugated drug and free payload PK, plus immunogenicity assessment. Oligonucleotides LC-MS quantification for PK when ligand-binding assays fall short. RNAs Molecular methods including qPCR, ddPCR and RNA-Seq for RNA therapeutics. Bi-specific, Tri-specific PK assays including total antibody, plus ADA and NAb assessment. Peptides High-sensitivity LC-MS methods for peptide quantification. Lipid nanoparticles Bioanalytical and immunogenicity support for LNP-delivered therapeutics. AAV Vectors qPCR and ddPCR for copy number and biodistribution, plus immunogenicity assays.

## Frequently Asked Questions

 

### What bioanalysis and biomarker services does Crystal Bio Solutions provide?

Crystal Bio Solutions supports pharmacokinetic (PK), immunogenicity (ADA and neutralizing antibody), pharmacodynamic and biomarker assays for biologics and novel modalities. Work covers assay strategy, method development, qualification and validation, sample analysis, and regulatory documentation, delivered from our GLP- and GCLP-compliant bioanalysis and biomarker laboratory in Pleasanton, California. Platforms include ligand-binding assays (ELISA, MSD, Gyrolab, Luminex, SP-X), triple quadrupole LC-MS/MS, cell-based assays, flow cytometry, ELISpot and molecular methods (qPCR, ddPCR, RNA-Seq, NGS). LC-MS method development for complex analytes is supported by HRMS expertise at our Natick, Massachusetts laboratory.

 

### How do you choose between a ligand-binding assay and LC-MS for a PK method?

Ligand-binding assays (LBA) offer high sensitivity for large molecules and are the usual choice for monoclonal antibodies and fusion proteins. LC-MS is preferred when specificity matters more than raw sensitivity, for example for ADC payloads, oligonucleotides, peptides, endogenous biomarkers, or when critical reagents for an LBA are not available. Hybrid LBA/LC-MS methods combine immunocapture with mass spectrometry detection. The choice depends on the molecule, the matrix, the required sensitivity and the study phase.

 

### What is a tiered immunogenicity assessment?

Regulators expect anti-drug antibody (ADA) evaluation in tiers: a screening assay, a confirmatory assay to establish specificity, and titer determination for confirmed positives. Neutralizing antibody (NAb) assays then assess whether ADA inhibit the drug's activity. Additional characterization, such as isotyping or domain specificity, is added when the risk profile requires it. Results are then related to PK, efficacy and safety data.

 

### When should a bioanalytical method be qualified versus fully validated?

Qualification (fit-for-purpose) is typical for discovery and exploratory biomarker work, where the method needs demonstrated reliability for internal decisions. Full validation is expected when data support regulatory decisions, such as PK and toxicokinetic data in pivotal nonclinical studies and clinical trials, following ICH M10 for chromatographic and ligand-binding PK assays. Biomarker assays are validated fit-for-purpose for their intended use. FDA's final guidance on bioanalytical method validation for biomarkers (April 2026) takes ICH M10 as the starting point, recommends full validation when the data support regulatory decisions, and recognizes that some M10 criteria may not apply to every biomarker assay.

 

### What is a receptor occupancy assay, and how is it measured?

A receptor occupancy (RO) assay measures the fraction of a drug's target that is bound by the drug on cells, usually in whole blood. It is typically run by flow cytometry using free-receptor, drug-bound and total-receptor formats. RO data link PK to target engagement and help support dose selection, especially for immunomodulatory antibodies. CBS designs, qualifies and runs flow cytometry RO and immunophenotyping assays.

 

### What is a total antibody (TAb) assay?

A total antibody assay quantifies antibody-derived drug, conjugated and unconjugated. Whether the result is independent of DAR and of target binding depends on the assay format and reagents, and is shown during method development and validation. It is a core PK analyte for ADCs and bispecific antibodies, where it is interpreted alongside conjugated-drug and free-payload measurements.

 

### What should sponsors look for in a CRO for PK and ADA bioanalysis?

Useful criteria include experience with the specific modality, access to both ligand-binding and LC-MS platforms, a track record of developing methods for complex molecules, a quality system suited to regulated studies, clear communication of data and deviations, and documentation that can go directly into regulatory submissions. Scientific leadership that can interpret immunogenicity and PK results together is also important.

 

### Which drug modalities does CBS support?

Monoclonal antibodies, bispecific and trispecific antibodies, antibody-drug conjugates (ADCs), oligonucleotides, RNA therapeutics, peptides, lipid nanoparticles (LNP) and AAV vectors, as well as small molecules where LC-MS is required.

 

### What documentation do you deliver for regulatory submissions?

Deliverables include method validation reports, sample analysis plans, bioanalytical data packages, integrated immunogenicity summaries, contributions to clinical study reports, and responses to agency questions, formatted for inclusion in regulatory submissions.

 

## Related articles & Related services

[ADC Programs: Integrated Analytical and Bioanalytical Support](https://www.crystalbiosolutions.com/antibody-drug-conjugates-adc?hsLang=en)

[NAb and ADA Assay Development and Validation](https://www.crystalbiosolutions.com/ada-and-nab-testing-in-biologics-pk-efficacy-and-regulatory-risk?hsLang=en)

[Extended Characterization of Biologics by High-Resolution Mass Spectrometry](https://www.crystalbiosolutions.com/services/biologics-extended-characterization-hrms?hsLang=en)

## Related case studies

- [An LC-MS/MS Method for Oligonucleotide PK Bioanalysis](https://www.crystalbiosolutions.com/news-and-events/a-lc-ms/ms-method-for-oligonucleotide-pk-bioanalysis?hsLang=en): An LC-MS/MS method for oligonucleotide quantitation in PK studies.
- [A Generic LC-MS/MS Solution for ADC PK Bioanalysis](https://www.crystalbiosolutions.com/news-and-events/a-generic-lc-ms/ms-solution-for-adc-pk-bioanalysis?hsLang=en): A generic LC-MS/MS workflow for total antibody and conjugated payload in ADC PK studies.
- [Receptor Occupancy of an Antibody Drug Measured by Flow Cytometry](https://www.crystalbiosolutions.com/news-and-events/receptor-occupancy-of-antibody-drug-measured-by-flow-cytometry?hsLang=en): Flow cytometry measurement of receptor occupancy for an antibody drug.
- [Immunophenotyping to Identify Peripheral Lymphocyte Subsets](https://www.crystalbiosolutions.com/news-and-events/immunophenotyping-to-identify-peripheral-lymphocyte-subsets?hsLang=en): A flow cytometry panel to identify peripheral lymphocyte subsets.
- [Sample Pretreatment Approaches to Improve Drug Tolerance in ADA Assays](https://www.crystalbiosolutions.com/news-and-events/pretreatment-approaches-to-improve-drug-tolerance-in-ada-assay?hsLang=en): Sample pretreatment options that improve ADA assay drug tolerance.

[See all case studies](https://www.crystalbiosolutions.com/news-and-events/tag/case-study?hsLang=en)

Discuss your assay with Dr. Meina Liang, our Chief Scientific Officer

Bring a real PK, immunogenicity, receptor occupancy or biomarker problem to the leader who supervises our bioanalysis projects. One hour at no cost, with a CDA in place first. Our business development team replies within one business day.

[Request a Consultation](https://www.crystalbiosolutions.com/scientific-consultation?hsLang=en)

## Ready to Start a Project?

Tell us about your study. Our business development team replies within one business day.

[Request a Proposal](https://www.crystalbiosolutions.com/contact-us?hsLang=en)

![Crystal Bio Solutions logo (footer)](https://www.crystalbiosolutions.com/hubfs/Logo_CBS-%E7%AB%96%E7%89%88-%E5%8F%8D%E7%99%BD.png)

- [Our Services](https://www.crystalbiosolutions.com) 
    - [Bioanalysis & Biomarkers](https://www.crystalbiosolutions.com/services/bioanalysis-and-biomarkers)
    - [Biologics CMC Analytical](https://www.crystalbiosolutions.com/characterization-cmc-analytical)
    - [Clinical Pharmacology](https://www.crystalbiosolutions.com/services/clinical-pharmacology)
    - [Regulatory Affairs](https://www.crystalbiosolutions.com/services/regulatory-affairs-biologics-adc-cgt)
    - [Clinical Support](https://www.crystalbiosolutions.com/clinical-research-services)
- [Information](https://www.crystalbiosolutions.com/news-and-events) 
    - [About Us](https://www.crystalbiosolutions.com/about-us)
    - [Quality & Compliance](https://www.crystalbiosolutions.com/quality-and-compliance)
    - [News & Events](https://www.crystalbiosolutions.com/news-and-events)
    - [Case Studies](https://www.crystalbiosolutions.com/news-and-events/tag/case-study)
    - [Scientific Articles](https://www.crystalbiosolutions.com/news-and-events/tag/blog)
    - [Careers](https://www.crystalbiosolutions.com/careers-at-crystal-bio-solutions)
- [Contact](https://www.crystalbiosolutions.com/contact-us) 
    - [Email Us](mailto:cbs_bd@crystalpharmatech.com)
    - [Contact Form](https://www.crystalbiosolutions.com/contact-us)
    - [Our Locations](https://www.crystalbiosolutions.com/locations)
    - [Crystal Group](https://www.crystalbiosolutions.com/about-us#crystal-group) 
          - [Crystal Pharmatech](https://www.crystalpharmatech.com/)
          - [Crystal NAX](https://www.crystalnax.com/)

<https://www.linkedin.com/company/crystal-bio-solutions/> [Follow us on LinkedIn News, events and openings](https://www.linkedin.com/company/crystal-bio-solutions/)

- [Privacy Policy](https://www.crystalbiosolutions.com/policies/privacy-policy)
- [Terms of Service](https://www.crystalbiosolutions.com/policies/terms-of-service)

Copyright © 2026 Crystal Bio Solutions, Inc. All rights reserved.

```json
{
  "@context" : "https://schema.org",
  "@id" : "https://www.crystalbiosolutions.com/#organization",
  "@type" : "Organization",
  "alternateName" : "CBS",
  "contactPoint" : [ {
    "@type" : "ContactPoint",
    "contactType" : "sales",
    "email" : "cbs_bd@crystalpharmatech.com",
    "url" : "https://www.crystalbiosolutions.com/contact-us"
  } ],
  "logo" : "https://www.crystalbiosolutions.com/hs-fs/hubfs/CBS%20VI%20v2/CBS%20Logo.png",
  "name" : "Crystal Bio Solutions",
  "parentOrganization" : {
    "@type" : "Organization",
    "name" : "Crystal Group",
    "url" : "https://www.crystalpharmatech.com/"
  },
  "sameAs" : [ "https://www.linkedin.com/company/crystal-bio-solutions/" ],
  "url" : "https://www.crystalbiosolutions.com/"
}
```

```json
{
  "@context" : "https://schema.org",
  "@id" : "https://www.crystalbiosolutions.com/#website",
  "@type" : "WebSite",
  "inLanguage" : "en",
  "name" : "Crystal Bio Solutions",
  "publisher" : {
    "@id" : "https://www.crystalbiosolutions.com/#organization"
  },
  "url" : "https://www.crystalbiosolutions.com/"
}
```

```json
{
  "@context" : "https://schema.org",
  "@id" : "https://www.crystalbiosolutions.com/services/bioanalysis-and-biomarkers/#webpage",
  "@type" : "WebPage",
  "about" : {
    "@id" : "https://www.crystalbiosolutions.com/services/bioanalysis-and-biomarkers/#service"
  },
  "breadcrumb" : {
    "@id" : "https://www.crystalbiosolutions.com/services/bioanalysis-and-biomarkers/#breadcrumb"
  },
  "description" : "PK, immunogenicity (ADA/NAb) and biomarker assay development and validation for mAbs, ADCs, oligonucleotides and CGT, with LBA, LC-MS and flow cytometry.",
  "inLanguage" : "en",
  "isPartOf" : {
    "@id" : "https://www.crystalbiosolutions.com/#website"
  },
  "name" : "Bioanalysis & Biomarker Services for Biologics | CBS",
  "url" : "https://www.crystalbiosolutions.com/services/bioanalysis-and-biomarkers"
}
```

```json
{
  "@context" : "https://schema.org",
  "@id" : "https://www.crystalbiosolutions.com/services/bioanalysis-and-biomarkers/#service",
  "@type" : "Service",
  "areaServed" : "Worldwide",
  "description" : "GLP- and GCLP-compliant bioanalytical and biomarker assay strategy, development, qualification, validation and sample analysis, with reports formatted for regulatory submission and central lab kit logistics.",
  "hasOfferCatalog" : {
    "@type" : "OfferCatalog",
    "itemListElement" : [ {
      "@type" : "Offer",
      "itemOffered" : {
        "@type" : "Service",
        "name" : "Immunoassays (ELISA, MSD, Gyrolab, Luminex, SP-X)"
      }
    }, {
      "@type" : "Offer",
      "itemOffered" : {
        "@type" : "Service",
        "name" : "LC-MS/MS (triple quadrupole)"
      }
    }, {
      "@type" : "Offer",
      "itemOffered" : {
        "@type" : "Service",
        "name" : "Cell-based assays"
      }
    }, {
      "@type" : "Offer",
      "itemOffered" : {
        "@type" : "Service",
        "name" : "Flow cytometry and receptor occupancy"
      }
    }, {
      "@type" : "Offer",
      "itemOffered" : {
        "@type" : "Service",
        "name" : "ELISpot"
      }
    }, {
      "@type" : "Offer",
      "itemOffered" : {
        "@type" : "Service",
        "name" : "Molecular biology (qPCR, ddPCR, NGS)"
      }
    } ],
    "name" : "Bioanalysis and Biomarker Services"
  },
  "name" : "Bioanalysis and Biomarker Services",
  "provider" : {
    "@id" : "https://www.crystalbiosolutions.com/#organization"
  },
  "url" : "https://www.crystalbiosolutions.com/services/bioanalysis-and-biomarkers"
}
```

```json
{
  "@context" : "https://schema.org",
  "@id" : "https://www.crystalbiosolutions.com/services/bioanalysis-and-biomarkers/#breadcrumb",
  "@type" : "BreadcrumbList",
  "itemListElement" : [ {
    "@type" : "ListItem",
    "item" : "https://www.crystalbiosolutions.com/",
    "name" : "Home",
    "position" : 1
  }, {
    "@type" : "ListItem",
    "item" : "https://www.crystalbiosolutions.com/services/bioanalysis-and-biomarkers",
    "name" : "Bioanalysis & Biomarkers",
    "position" : 2
  } ]
}
```

```json
{
  "@context" : "https://schema.org",
  "@id" : "https://www.crystalbiosolutions.com/services/bioanalysis-and-biomarkers/#faq",
  "@type" : "FAQPage",
  "mainEntity" : [ {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "Crystal Bio Solutions supports pharmacokinetic (PK), immunogenicity (ADA and neutralizing antibody), pharmacodynamic and biomarker assays for biologics and novel modalities. Work covers assay strategy, method development, qualification and validation, sample analysis, and regulatory documentation, delivered from our GLP- and GCLP-compliant bioanalysis and biomarker laboratory in Pleasanton, California. Platforms include ligand-binding assays (ELISA, MSD, Gyrolab, Luminex, SP-X), triple quadrupole LC-MS/MS, cell-based assays, flow cytometry, ELISpot and molecular methods (qPCR, ddPCR, RNA-Seq, NGS). LC-MS method development for complex analytes is supported by HRMS expertise at our Natick, Massachusetts laboratory."
    },
    "name" : "What bioanalysis and biomarker services does Crystal Bio Solutions provide?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "Ligand-binding assays (LBA) offer high sensitivity for large molecules and are the usual choice for monoclonal antibodies and fusion proteins. LC-MS is preferred when specificity matters more than raw sensitivity, for example for ADC payloads, oligonucleotides, peptides, endogenous biomarkers, or when critical reagents for an LBA are not available. Hybrid LBA/LC-MS methods combine immunocapture with mass spectrometry detection. The choice depends on the molecule, the matrix, the required sensitivity and the study phase."
    },
    "name" : "How do you choose between a ligand-binding assay and LC-MS for a PK method?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "Regulators expect anti-drug antibody (ADA) evaluation in tiers: a screening assay, a confirmatory assay to establish specificity, and titer determination for confirmed positives. Neutralizing antibody (NAb) assays then assess whether ADA inhibit the drug's activity. Additional characterization, such as isotyping or domain specificity, is added when the risk profile requires it. Results are then related to PK, efficacy and safety data."
    },
    "name" : "What is a tiered immunogenicity assessment?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "Qualification (fit-for-purpose) is typical for discovery and exploratory biomarker work, where the method needs demonstrated reliability for internal decisions. Full validation is expected when data support regulatory decisions, such as PK and toxicokinetic data in pivotal nonclinical studies and clinical trials, following ICH M10 for chromatographic and ligand-binding PK assays. Biomarker assays are validated fit-for-purpose for their intended use. FDA's final guidance on bioanalytical method validation for biomarkers (April 2026) takes ICH M10 as the starting point, recommends full validation when the data support regulatory decisions, and recognizes that some M10 criteria may not apply to every biomarker assay."
    },
    "name" : "When should a bioanalytical method be qualified versus fully validated?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "A receptor occupancy (RO) assay measures the fraction of a drug's target that is bound by the drug on cells, usually in whole blood. It is typically run by flow cytometry using free-receptor, drug-bound and total-receptor formats. RO data link PK to target engagement and help support dose selection, especially for immunomodulatory antibodies. CBS designs, qualifies and runs flow cytometry RO and immunophenotyping assays."
    },
    "name" : "What is a receptor occupancy assay, and how is it measured?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "A total antibody assay quantifies antibody-derived drug, conjugated and unconjugated. Whether the result is independent of DAR and of target binding depends on the assay format and reagents, and is shown during method development and validation. It is a core PK analyte for ADCs and bispecific antibodies, where it is interpreted alongside conjugated-drug and free-payload measurements."
    },
    "name" : "What is a total antibody (TAb) assay?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "Useful criteria include experience with the specific modality, access to both ligand-binding and LC-MS platforms, a track record of developing methods for complex molecules, a quality system suited to regulated studies, clear communication of data and deviations, and documentation that can go directly into regulatory submissions. Scientific leadership that can interpret immunogenicity and PK results together is also important."
    },
    "name" : "What should sponsors look for in a CRO for PK and ADA bioanalysis?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "Monoclonal antibodies, bispecific and trispecific antibodies, antibody-drug conjugates (ADCs), oligonucleotides, RNA therapeutics, peptides, lipid nanoparticles (LNP) and AAV vectors, as well as small molecules where LC-MS is required."
    },
    "name" : "Which drug modalities does CBS support?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "Deliverables include method validation reports, sample analysis plans, bioanalytical data packages, integrated immunogenicity summaries, contributions to clinical study reports, and responses to agency questions, formatted for inclusion in regulatory submissions."
    },
    "name" : "What documentation do you deliver for regulatory submissions?"
  } ],
  "url" : "https://www.crystalbiosolutions.com/services/bioanalysis-and-biomarkers"
}
```